| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S100A9 |
| Uniprot No | P06702 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-114aa |
| 氨基酸序列 | MTCKMSQLER NIETIINTFH QYSVKLGHPD TLNQGEFKEL VRKDLQNFLK KENKNEKVIE HIMEDLDTNA DKQLSFEEFI MLMARLTWAS HEKMHEGDEG PGHHHKPGLG EGTPLEHHHH HH |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"S100A9 recombinant protein induces pro-inflammatory cytokines in macrophages via TLR4/NF-κB pathway"**
- 作者：Vogl T, et al.
- 摘要：研究通过重组S100A9蛋白激活巨噬细胞中TLR4/NF-κB信号通路的机制，证实其促进IL-6、TNF-α等炎症因子释放，揭示了其在慢性炎症疾病中的潜在作用。
2. **"Recombinant S100A9 enhances tumor growth by modulating myeloid-derived suppressor cells in the tumor microenvironment"**
- 作者：Gebhardt C, et al.
- 摘要：通过体外重组S100A9蛋白实验，发现其通过招募并激活MDSCs(髓系来源抑制细胞)，抑制T细胞抗肿瘤活性，从而促进肿瘤免疫逃逸及进展。
3. **"Structural and functional characterization of recombinant S100A9 in autoimmune arthritis"**
- 作者：Srikrishna G, et al.
- 摘要：解析重组S100A9蛋白的锌离子结合特性，证明其通过增强RAGE受体信号通路，加剧类风湿性关节炎模型中的滑膜炎症和骨破坏。
4. **"Recombinant S100A9 acts as a damage-associated molecular pattern in sepsis"**
- 作者：Robinson MJ, et al.
- 摘要：发现重组S100A9在脓毒症模型中作为DAMP分子，通过激活内皮细胞释放趋化因子(如CXCL8)，导致中性粒细胞浸润和多器官损伤。
每篇文献聚焦不同病理场景(炎症、肿瘤、自身免疫、感染)，均利用重组蛋白验证S100A9的生物学功能及机制。
S100A9. also known as calgranulin B or myeloid-related protein 14 (MRP14), is a calcium- and zinc-binding protein belonging to the S100 family. It typically forms a heterodimer with S100A8 (MRP8), collectively termed calprotectin, which plays critical roles in innate immunity and inflammatory responses. Expressed predominantly in neutrophils, monocytes, and activated macrophages, S100A9 functions as a damage-associated molecular pattern (DAMP) molecule, released during cellular stress or tissue injury to activate immune pathways via receptors like Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE).
Recombinant S100A9 protein is engineered using expression systems such as *E. coli* or mammalian cells, enabling controlled production for research and therapeutic applications. Its recombinant form retains the ability to bind divalent cations and interact with target receptors, making it a valuable tool for studying inflammatory mechanisms, leukocyte recruitment, and cytokine regulation. Researchers utilize it to model sterile inflammation, sepsis, or autoimmune diseases, where S100A9 overexpression correlates with pathogenesis, including rheumatoid arthritis, inflammatory bowel disease, and cancer metastasis.
In drug development, recombinant S100A9 aids in screening inhibitors targeting its pro-inflammatory activity. It also serves as a biomarker in diagnostic assays for conditions like cardiovascular diseases or neurodegenerative disorders, where elevated levels signal chronic inflammation. However, challenges remain in mimicking post-translational modifications (e.g., oxidation, phosphorylation) inherent to native S100A9. which may influence its biological activity. Ongoing studies focus on optimizing recombinant variants to better replicate physiological behavior, advancing its utility in both mechanistic research and clinical applications.
×
